Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Additional Metadata
Persistent URL	doi.org/10.1016/S0140-6736(01)06844-1, hdl.handle.net/1765/58674
Journal	The Lancet
Organisation	Department of Internal Medicine
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	van der Lely, A.-J., Hutson, N., Trainer, P., Besser, G. M., Barkan, A., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., Freda, P., Stewart, P. M., Friend, K., Clemmons, D., Johannsson, G., Stavrou, E., Cook, D., Phillips, L., Strasburger, C. J., … Thorner, M. (2001). Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet, 358(9295), 1754–1759.https://doi.org/10.1016/S0140-6736(01)06844-1

Publication